Evidence map›Paper›PMID 41061175›Full record

ArticleJCO global oncology2025

Barriers and Facilitators to Cancer Clinical Trial Participation: Perspectives of Patients in the ICON-3 Practice-Based Research Network, Nigeria.

Ngozi Idemili-Aronu, Babayemi O Olakunde, Tara M Friebel-Klingner, Adaeze Chike-Okoli, Ijeoma U Itanyi, Tonia C Onyeka, Anne F Rositch, Richard B S Roden, Tzyy-Choou Wu, Echezona E Ezeanolue and 1 more

Abstract read
In one paragraph

Article in JCO global oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ngozi Idemili-AronuIVAN Research Institute, University of Nigeria Nsukka, Enugu, Nigeria.ORCID 0000-0001-9719-8153
Babayemi O OlakundeIVAN Research Institute, University of Nigeria Nsukka, Enugu, Nigeria.
Tara M Friebel-KlingnerRutgers Global Health Institute, New Brunswick, NJ.ORCID 0000-0002-3726-9527
Adaeze Chike-OkoliDepartment of Sociology/Anthropology, University of Nigeria Nsukka, Enugu, Nigeria.ORCID 0009-0008-1888-4891
Ijeoma U ItanyiIVAN Research Institute, University of Nigeria Nsukka, Enugu, Nigeria.ORCID 0000-0002-4958-6319
Tonia C OnyekaIVAN Research Institute, University of Nigeria Nsukka, Enugu, Nigeria.ORCID 0000-0001-8138-3100
Anne F RositchDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.ORCID 0000-0002-0403-8482
Richard B S RodenDepartment of Pathology, Johns Hopkins Medical Institutes, Baltimore, MD.
Tzyy-Choou WuDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Echezona E EzeanolueIVAN Research Institute, University of Nigeria Nsukka, Enugu, Nigeria.ORCID 0000-0002-6294-9479
Kimberly LevinsonDepartment of Gynecology and Obstetrics, Johns Hopkins Medical Institutes, Baltimore, MD.ORCID 0000-0002-6457-9635

Funding

Treatment of HIV- and HIV+ Patients with HPV16+ CIN2/3 Using pNGLV4a-hCRTE6E7L2 DNA vaccine administered intramuscularly via electroporationP50CA098252 · NCI · JOHNS HOPKINS UNIVERSITY · PI WARNER KING HUH, TZYY-CHOOU WU · 2003 to 2026
$53.5M
ACCESS: Accelerating Cervical Cancer Elimination through the integration of Screen-and-treat ServicesU01CA275118 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GREGORY AARONS, Echezona Edozie Ezeanolue · 2022 to 2026
$3.5M
NCI NIH HHS P50 CA098252NCI NIH HHS U01 CA275118
6 · The paper itself

Abstract

purposeAfrica faces a growing burden of cancer yet remains under-represented in global cancer clinical trials. This disparity limits the generation of population-specific evidence needed to improve cancer outcomes. Recruitment and retention in cancer clinical trials are particularly challenging because of various systemic and individual barriers in Nigeria. This study explores patients' perspectives on barriers and facilitators to recruitment and retention in cancer clinical trials.

methodsA convergent parallel mixed-methods design was used, which comprised a cross-sectional survey and a descriptive qualitative approach. Participants were recruited from multiple oncology centers and secondary facilities within Nigeria's ICON-3 Practice-Based Research Network. Quantitative data were collected through interviewer-administered questionnaires, whereas qualitative data were gathered via semistructured interviews and analyzed thematically.

resultsA total of 317 patients participated in the quantitative survey, 18 of whom participated in interviews. Barriers included limited understanding of clinical trials, logistical challenges such as transportation and visit frequency, distrust in researchers and the health care system, and lack of family support. Facilitators included effective communication, incentives, flexible research visits, and culturally tailored interventions.

conclusionTo optimize cancer clinical trial participation in low-resource settings, interventions must be tailored to local contexts, addressing structural and cultural barriers. Enhanced communication, community involvement, and supportive policies can significantly improve trial participation and outcomes.

Indexed as

Clinical Trials as TopicNeoplasmsPatient ParticipationAdultAgedCross-Sectional StudiesFemaleHumansMaleMiddle AgedNigeriaPatient SelectionSurveys and Questionnaires

Identifiers

PMID41061175
PMCPMC12679331

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.